GROW.L

Molten Ventures plc
Molten Ventures PLC - Hologic, Inc. to Acquire Endomagnetics
30th April 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 5631M
Molten Ventures PLC
30 April 2024
 

30 April 2024

 

Molten Ventures plc

("Molten", the "Group" or the "Company")

Hologic Inc. to acquire Endomagnetics for approx. $310m

Molten Ventures plc (LSE: GROW, Euronext Dublin: GRW), a leading venture capital firm investing in and developing high growth digital technology businesses, notes the announcement released by Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, that it is has signed a definitive agreement to acquire Endomagnetics Ltd. ('Endomag'). The acquisition, which is subject to regulatory approval as well as working capital and other customary closing adjustments values Endomag at approximately $310m.

Endomag is a medical technology company, based in Cambridge, devoted to improving the global standard of care in breast cancer. Its products include the Magseed® marker for magnetic tissue localisation before surgery, the Magtrace® lymphatic tracing injectable for breast cancer staging and the Sentimag® platform, which supports both localisation and lymphatic tracing.

Molten first invested in Endomag in July 2018, with investment from its balance sheet and from its EIS and VCT funds. Follow-on funding was provided to support Endomag's continued growth in 2020. The deal values Molten's stake in Endomag modestly above its Group holding value of £35 million.

In its recent trading update, published 23 April 2024, Molten noted that FY25 was showing promise of a more normalised realisations market, with proceeds expected to be meaningfully higher than the prior two years. The announcement of the acquisition of Endomag follows Molten's recent announcement of the proposed exit of Perkbox (announced on 18 March 2024 and subject to regulatory approval).

Martin Davis, Chief Executive Officer of Molten Ventures, commented:

"This transaction, alongside Perkbox, demonstrates our ability to support innovative businesses as they scale and create value for our shareholders through the cycle.

"The news follows our recent announcement in relation to Perkbox, and reflects the additional momentum being seen in the realisations market. With multiple realisation processes either underway or planned across the portfolio we expect to deliver in the region of £100 million of capital back to the balance sheet this financial year.

"We will provide an update on our capital allocation policy in respect of these anticipated proceeds, which focuses on NAV per share accretive deployment, at the time of our full year results on 12 June 2024."

 

-ENDS-

 

Enquiries:

 

Molten Ventures plc

Martin Davis (Chief Executive Officer)

Ben Wilkinson (Chief Financial Officer)

 

+44 (0)20 7931 8800

ir@molten.vc

 

Deutsche Numis

Joint Financial Adviser and Corporate Broker 

Simon Willis

Jamie Loughborough

Iqra Amin

 

+44 (0)20 7260 1000

 

Goodbody Stockbrokers

Joint Financial Adviser and Corporate Broker,

Euronext Dublin Sponsor

Don Harrington

Dearbhla Gallagher

William Hall

 

+44 (0) 20 3841 6202

 

Powerscourt

Public relations

Elly Williamson

Nick Hayns

 

+44 (0)7970 246 725

/ +44 (0)7880 744 379

molten@powerscourt-group.com

About Molten Ventures

 

Molten Ventures is a leading venture capital firm in Europe, developing and investing in disruptive, high growth technology companies. We inject visionary companies with energy to help them transform and grow. This energy comes in many forms - capital, of course, but also knowledge, experience, and relationships. We believe it is our role to support the entrepreneurs who will invent the future, and that future is being built, today, in Europe.

 

As at 30 September 2023, Molten Ventures had a diverse portfolio with shareholdings in 74 companies, 17 of which represent our Core Portfolio holdings and account for 62% of the Gross Portfolio Value. Our core companies include Thought Machine, Coachhub, Form3, Aiven, Ledger and Aircall. We invest across four sectors: Enterprise Technology, Hardware and Deeptech, Consumer Technology, and Digital Health and Wellness, with highly experienced partners constantly looking for new opportunities in each. We look for high-growth companies operating in new markets, with aspirations for global expansion, strong IP, powerful technology, and strong management teams to deliver success. We also look for businesses with the potential to generate strong margins to ensure rapid, sustainable growth in substantial addressable markets.

 

Molten Ventures provides a unique opportunity for public market investors to access these fast-growing tech businesses, without having to commit to long term investments with limited liquidity. Since our IPO in June 2016, we have deployed over £1bn capital into fast growing tech companies and have realised £520m to 30 September 2023.

 

For more information, go to https://www.moltenventures.com/

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMZGFDKGVGDZG]]>
TwitterFacebookLinkedIn